Chris Calise - Mar 4, 2025 Form 4 Insider Report for Coeptis Therapeutics Holdings, Inc. (COEP)

Role
Director
Signature
/s/ Christopher Calise
Stock symbol
COEP
Transactions as of
Mar 4, 2025
Transactions value $
$0
Form type
4
Date filed
3/6/2025, 05:26 PM
Previous filing
Aug 31, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COEP Non-qualified Stock Options (right to buy) Award +5.7K +175.38% 8.95K Mar 4, 2025 Common Stock 5.7K $10.56 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 4, 2025, the reporting person received a grant of 5,700 stock options, as non-qualified options, under the 2022 equity incentive plan.
F2 The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Capital Market on the day of grant.
F3 Non-qualified options will vest over 1 year, in four equal installments, with the first 25% vesting on 3/31/2025, the next 25% vesting on 6/30/2025, the next 25% vesting on 9/30/25, and the final 25% vesting on 12/31/25.
F4 Expiration date is ten years from the day of grant.